Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Jacobio Pharmaceuticals (1167 HK)
Watchlist
64
Analysis
Health Care
•
China
Jacobio Pharmaceuticals Co. Ltd. operates as a biotech company. The Company develops and sells cancer innovative drugs, autoimmune drugs, infectious diseases drugs, and other products. Jacobio Pharmaceuticals markets its products throughout China.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Jacobio Pharmaceuticals
•
10 Dec 2020 08:24
Jacobio: Management Solves for Valuation
We think that the offer terms for Jacobio's IPO are fair, but buyers need to take a long view given the small deal size and shares' limited liquidity.
Kemp Dolliver, CFA
249 Views
Share
bullish
•
Jacobio Pharmaceuticals
•
08 Dec 2020 09:23
Pre-IPO Jacobio Pharmaceuticals - Insights on Pipeline
This article analyzed the compelling and distinctive pipeline of Jacobio Pharmaceuticals in terms of projects. Meanwhile, it also disclose the...
Xinyao (Criss) Wang
Follow
397 Views
Share
bullish
•
Jacobio Pharmaceuticals
•
05 Dec 2020 16:47
Jacobio Pharma IPO Initiation: Drugging the Undruggable
Jacobio is seeking to raise $300 million through a Hong Kong IPO. Overall, we believe that Jacobio’s clinical assets are attractive.
Arun George
Follow
403 Views
Share
bullish
•
Jacobio Pharmaceuticals
•
04 Dec 2020 08:29
Jacobio: Updated Valuation and Other Thoughts
This Insight updates our NPV (reduce by ~US$100MM) of Jacobio, analyzes the use of proceeds, and has a list of 2021 events. We will give our...
Kemp Dolliver, CFA
413 Views
Share
bullish
•
Jacobio Pharmaceuticals
•
21 Nov 2020 00:08
Jacobio Pharma: More Thinking on Valuation
Our DCF analysis of Jacobio Pharma results in a US$1.1B pre-money valuation based on the company's lead compounds and the AbbVie license agreement....
Kemp Dolliver, CFA
359 Views
Share
First
Previous
8
9
10
11
12
13
Next
Last
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.33.9
x